At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,110 enrolled
Drug / intervention
Pazopanib +1 moredrug
Likely dose
Pazopanib 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study VEG108844, A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
In Brief
A Phase 3 clinical trial evaluating Pazopanib and Sunitinib for Carcinoma, Renal Cell. Completed, enrolled 1,110 participants across 227 sites in 14 countries.
Detailed Summary
This was a randomized, open-label, parallel group Phase III non inferiority study to evaluate the efficacy and safety of pazopanib compared with sunitinib in subjects with advanced renal cell carcinoma (RCC) who had not received prior systemic therapy for advanced or metastatic RCC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesAustralia, Canada, China, Germany, Ireland, Italy, Japan, Netherlands, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartAug 2008
Primary CompletionMay 2012
Study CompletionMar 2021
TodayJul 2026
First PostedJul 23, 2008
Enrollment StartAug 14, 2008
Primary CompletionMay 21, 2012
Study CompletionMar 24, 2021
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 17.9 years ago
Interventions
Pazopanibdrug
800 mg administered once daily orally continuous dosing
Sunitinibdrug
50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment